Answers are grounded in this paper and cite their sources.
Background Leprosy (Hansen's disease) remains a major chronic infectious disease with substantial physical disabling potential and enduring social stigma. While multidrug therapy (MDT) is curative, its prolonged course and high frequency of adverse drug reactions severely challenge patient adherence, predisposing individuals to therapeutic failure, clinical relapses, and bacillary drug resistance. Objective To critically analyze, through an integrative literature review, the impact of pharmaceutical care on medication adherence and the promotion of pharmacotherapy safety among patients undergoing treatment for leprosy. Methods A comprehensive bibliographic search was conducted across SciELO, PubMed/MEDLINE, LILACS, and Google Scholar for studies published between January 1997 and August 2026, combining standardized DeCS/MeSH terms and Boolean operators in English, Portuguese, and Spanish. Following screening and eligibility assessment, seven peer-reviewed studies (original research and reviews) met all criteria and constituted the central analytical corpus. Results Adherence to MDT across healthcare services is frequently suboptimal, primarily driven by debilitating adverse drug events (such as hemolysis, methemoglobinemia, severe xerosis, and cutaneous hyperpigmentation), forgetfulness, treatment complexity, and socioeconomic vulnerability. Clinical pharmaceutical interventions—encompassing structured pharmacotherapeutic follow-up (Dáder Method), patient health education, and active pharmacovigilance—demonstrated unequivocal effectiveness. Clinical investigations reported a 100% acceptance rate for pharmaceutical interventions, culminating in the comprehensive resolution of drug-related problems (DRPs) and the effective management of drug toxicity, thereby preventing treatment abandonment. Conclusion Integrating pharmacists into primary care multidisciplinary teams strengthens the therapeutic alliance, substantially curtails treatment abandonment, and ensures safe completion of therapy through to microbiological and clinical cure.
No takes yet. Share an insight, caveat, or question.
Filho et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: